Loading news...
Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
– Approximately $44 million and $125 million in preliminary (unaudited) Revuforj ® (revumenib) 4Q25 and full year 2025 net revenue, respectively – – Continued acceleration in demand following approval in R/R NPM1m AML, with an approximate 38% increase in Revuforj net revenue in 4Q25 vs. 3Q25 - – $56 million and $152 million in preliminary (unaudited) Niktimvo™ (axatilimab-csfr) 4Q25 and full year 2025 net revenue, respectively; Syndax will report its share of the Niktimvo net profit when it reports full year 2025 results – – Ended 2025 with approximately $394 million in cash, cash equivalents and marketable securities (unaudited); fully funded through profitability – – Syndax to present at the 44 th Annual J.P.
- Program will expand access in certain regions where Revuforj is not available commercially, as permitted by local regulations - - Program will be launched in parts of Eurasia, Central and Southeast Europe, Israel, the Middle East and Turkey, Latin America, and Africa - NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX) and the World Orphan Drug Alliance (WODA) today announced a collaboration to expand access to the Company's first-in-class menin inhibitor, Revuforj® (revumenib), through a Managed Access Program. This program enables physicians to prescribe Revuforj to appropriate patients outside the U.S. where the drug is not approved but access to novel medicines is permitted by local regulations and where funding can be secured.
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the twelve research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, nine have given a buy recommendation and one
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 3:00 p.m. PT/ 6:00 p.m. ET.
Shares of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX - Get Free Report) reached a new 52-week high on Tuesday. The stock traded as high as $21.50 and last traded at $21.48, with a volume of 1371684 shares traded. The stock had previously closed at $20.77. Wall Street Analysts Forecast Growth SNDX has been the topic of
Syndax Pharmaceuticals is now a commercial-stage biopharma with two FDA-approved drugs: Revuforj and Niktimvo. SNDX's Revuforj leads in efficacy for AML, with rapid market penetration and a first-mover advantage in front-line Phase 3 trials. Despite cardiac risk concerns, lower-dose combination data suggest manageable safety, supporting SNDX's strong buy rating.
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (revumenib) was named Best New Drug at the Scrip Awards 2025, held by Citeline. The Best New Drug Award recognizes excellence in pharmaceutical development and the drug that represents the best therapeutic advance in its area.
Syndax Pharmaceuticals, Inc. (SNDX) Presents at The 67th American Society of Hematology (ASH) Annual Meeting Transcript
Stock News China's trade surplus tops $1T YTD: China's exports rose 5.9% in November while imports grew 1.9%, pushing the 11âmonth surplus to nearly $1.08 tri
– First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute leukemia pts –
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on December 1, 2025, the Company granted inducement awards to purchase up to 15,500 shares of common stock to one new employee under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025, at 11:15 a.m. ET.
Syndax Pharmaceuticals (SNDX) posted strong Q3 results, driven by robust Revuforj and Niktimvo sales, despite a slight revenue miss. SNDX's commercial ramp is accelerating, with Revuforj prescriptions up 25% and management confident cash reserves will fund operations to profitability. 2026 revenue projections for SNDX range from $245M to $512M, depending on growth scenarios, but risks include reimbursement and competitive shifts.
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX - Get Free Report)'s stock price was up 10.9% during mid-day trading on Monday after Barclays raised their price target on the stock from $22.00 to $35.00. Barclays currently has an overweight rating on the stock. Syndax Pharmaceuticals traded as high as $19.52 and last traded at $19.3450. Approximately 1,921,125 shares
Campbell and CO Investment Adviser LLC purchased a new stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 46,829 shares of the company's stock, valued at approximately $439,000. Campbell and CO Investment Adviser
Syndax Pharmaceuticals, Inc. ( SNDX ) UBS Global Healthcare Conference 2025 November 10, 2025 11:00 AM EST Company Participants Michael Metzger - CEO & Director Nicholas Botwood - Head of Research & Development and Chief Medical Officer Steven Closter - Chief Commercial Officer Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Xiaochuan Dai UBS Investment Bank, Research Division Okay. Well, thanks for joining.
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on November 1, 2025, the Company granted inducement awards to purchase up to 143,500 shares of common stock to four new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
Syndax Pharmaceuticals, Inc. remains a Buy, with Revuforj and Niktimvo launches accelerating and a strong clinical and commercial trajectory into 2026. Revuforj's recent NPM1 AML approval expands its addressable market, reinforcing first-mover advantage and supporting $1B+ peak sales potential. Niktimvo's robust uptake and Incyte partnership will aid the march to profitability, while also providing significant downside cushion.
Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.7 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to a loss of $0.98 per share a year ago.